Replies to post #673037 on NorthWest Biotherapeutics Inc (NWBO)

[flipper44]

I think it’s pretty straight forward Ex, but you can ask LL if you’d like.

Maybe it would help you to remember progression for purposes of the orginal pfs endpoint was done by icon only.

While that alone would lead to inevitable confoundment due to psPD, the procedure to crossover was more thorough.

If you recall, icon was not enough for LL to allow patients to crossover, they had to wait a month or a little longer until they could confirm it.

If you also recall, the field has a pretty good handle on Stupp protocol progressions, when further confirmation like that above is included. It’s the other arm (treatment arm that initially received DCVax) , that wasn’t utilized for the rGBM secondary endpoint that would have perplexed researchers (because of t-cell infiltration).

When the UK was given the MAA submission, you can bet the rGBM patients were cPD rGBM patients.

Imo.